CFM
ITOS

Catalyst Funds Management’s iTeos Therapeutics ITOS Stock Holding History

Catalyst Funds Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,000
Closed -$430K – 1453
2024
Q2 		$430K Sell
29,000
-4,700
-14% -$67.3K 0.12% 122
2024
Q1 		$460K Buy
+33,700
New +$367K 0.13% 141

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Catalyst Funds Management's ITOS Position: Q3 2024 in Review

Catalyst Funds Management sold out of iTeos Therapeutics (ITOS) in Q3 2024, closing a stake of 29,000 shares — an estimated $430K sold.

Catalyst Funds Management first reported a position in ITOS in Q1 2024 and held it in 2 quarters. The position peaked at $460K in Q1 2024. 150 funds tracked by Wall St. Rank hold ITOS as of Q3 2024.

  • Catalyst Funds Management reported no remaining iTeos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 29,000 iTeos Therapeutics shares in Q3 2024, an estimated $430K.
  • Catalyst Funds Management first reported a position in iTeos Therapeutics in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's iTeos Therapeutics position peaked at $460K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.